It’s that time of year already and it has come around so fast in 2017… yes it’s the annual meeting for the Society for Immunotherapy of Cancer (aka SITC).
This year there are several eagerly anticipated presentations, one of which is Juno’s ill-fated ROCKET trial in adult ALL using their JCAR015 CAR T cell therapy.
While Novartis and Kite both successfully made it to market recently in pediatric ALL and aggressive lumphomas, respectively, Juno were left languishing in a poor third place after a series of lethal cerebral oedemas scuppered the program. In the meantime, Novartis are relentless chasing Kite with their JULIET trial in DLBCL and could well have the third CAR T cell therapy indication.
Finally, we heard for the first time today what the company learned from the recent analysis of the deaths, which they shared with the field this morning. BSB was on the spot to hear more about what the CMO, Dr Mark Gilbert had to say and we also have some thought leader sentiments on their perspective of the findings.
That’s not all though, as there was also new data on checkpoint blockade and other immunotherapies that are in early development as well as developments on the biomarker front.